Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

Patent Application for Cell Manipulation Device and Method

The USPTO has published a new patent application (US20260086001A1) for a cell manipulation device and method. The application, filed on December 1, 2025, describes a technique for culturing cells by attaching them to an air bubble formed in a liquid flow path. This is a routine publication of a patent application.

Routine Notice Healthcare
Favicon for changeflow.com

Cardio-Tox TEEM Model for Cardiotoxicity and Arrhythmia Risk Assessment

The USPTO has published a patent application detailing the Cardio-Tox Tissue Engineered Model (TEEM). This in vitro model uses 3D human heart microtissues to assess cardiotoxicity and arrhythmia risk from test compounds, aiming to establish safe human exposure levels for environmental and pharmaceutical substances.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Viscoelastic Hydrogel Regulates Organoid Patterning and Vascularization

The USPTO has published a new patent application, US20260086082A1, detailing a viscoelastic hydrogel for regulating organoid patterning and vascularization. The application, filed by inventors Changchun Zeng, Yan Li, and Xingchi Chen, focuses on a spinal cord model.

Routine Notice Healthcare
Favicon for changeflow.com

Viscoelastic Hydrogel Regulates Organoid Patterning and Vascularization

The USPTO has published a new patent application, US20260086081A1, detailing a viscoelastic hydrogel for regulating organoid patterning and vascularization. The application, filed on April 10, 2025, describes spinal cord models using methacrylated hyaluronic acid and dopamine-modified hyaluronic acid.

Routine Notice Healthcare
Favicon for changeflow.com

Ovarian and Uterine Organoid Production and Pharmaceutical Screening

The USPTO has published a patent application detailing methods for producing ovarian and uterine organoids from stem cells. These organoids are intended for use in screening pharmaceutical interventions for diseases and for applications in hormone replacement therapy and assisted reproduction technologies.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Enzyme-containing article with water barrier properties

The USPTO has published a new patent application, US20260085163A1, detailing an enzyme-containing biodegradable single-layer article with water barrier properties. The application was filed by Vincent Legrand and includes various CPC classifications related to polymers and enzymes.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent Application: Method of Differentiating Pluripotent Stem Cells to Hematopoietic Cells

The USPTO has published a patent application (US20260085288A1) detailing a method for differentiating pluripotent stem cells into hematopoietic precursor and stem cells. The application, filed by Boris Greber and Daniel Terheyden-Keighley, outlines a process using specific induction cocktails for generating immune cells like NK cells.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Therapeutic Macrophages Patent Application

The USPTO has published a patent application (US20260085287A1) filed by Resolution Therapeutics Limited for therapeutic macrophages genetically engineered to overexpress Interleukin-10 (IL-10) or IL-10 in combination with Matrix Metallopeptidase 9 (MMP9). This application relates to potential treatments for inflammatory conditions.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Anti-tumor immune response enhancer patent application

The USPTO has published a new patent application, US20260085286A1, detailing an 'Anti-tumor immune response enhancer'. The application, filed by Kenichiro Hasumi, describes a composition comprising phospholipids to enhance anti-tumor activity and induce cytokine production.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Methods for Producing Retinal Pigment Epithelium Cells

The USPTO has published a new patent application detailing methods for producing retinal pigment epithelium (RPE) cells. The application describes specific culturing and replating techniques using laminin substrates to expand and mature RPE cells for potential therapeutic uses.

Routine Notice Pharmaceuticals

Showing 4101–4110 of 32,996 changes

1 409 410 411 412 413 3300

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.